These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 22722185)

  • 1. Drug discovery: computer model predicts side effects.
    Kolaja K
    Nature; 2012 Jun; 486(7403):326-7. PubMed ID: 22722185
    [No Abstract]   [Full Text] [Related]  

  • 2. New technologies in drug metabolism and toxicity screening: organ-to-organ interaction.
    Bhushan A; Martucci NJ; Usta OB; Yarmush ML
    Expert Opin Drug Metab Toxicol; 2016 May; 12(5):475-7. PubMed ID: 26940609
    [No Abstract]   [Full Text] [Related]  

  • 3. Assessing drug safety in human tissues - what are the barriers?
    Holmes A; Bonner F; Jones D
    Nat Rev Drug Discov; 2015 Aug; 14(8):585-7. PubMed ID: 26205467
    [No Abstract]   [Full Text] [Related]  

  • 4. Perspective of humanized mouse models for assessing PK/PD and toxic profile of drug candidates in preclinical study.
    Chiba K
    Drug Metab Pharmacokinet; 2014; 29(1):1-2. PubMed ID: 24573168
    [No Abstract]   [Full Text] [Related]  

  • 5. Drugs in control samples in nonclinical safety studies: a reconsideration.
    Zimmer D
    Bioanalysis; 2016 May; 8(10):1003-7. PubMed ID: 27080047
    [No Abstract]   [Full Text] [Related]  

  • 6. Evaluation of the use of in vitro methodologies as tools for screening new compounds for potential in vivo toxicity.
    Luber-Narod J; Smith B; Grant W; Jimeno JM; López-Lázaro L; Faircloth GT
    Toxicol In Vitro; 2001; 15(4-5):571-7. PubMed ID: 11566593
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety immunopharmacology: evaluation of the adverse potential of pharmaceuticals on the immune system.
    Descotes J
    J Pharmacol Toxicol Methods; 2012 Sep; 66(2):79-83. PubMed ID: 22587937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Large-scale prediction and testing of drug activity on side-effect targets.
    Lounkine E; Keiser MJ; Whitebread S; Mikhailov D; Hamon J; Jenkins JL; Lavan P; Weber E; Doak AK; Côté S; Shoichet BK; Urban L
    Nature; 2012 Jun; 486(7403):361-7. PubMed ID: 22722194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Towards better models and mechanistic biomarkers for drug-induced gastrointestinal injury.
    Carr DF; Ayehunie S; Davies A; Duckworth CA; French S; Hall N; Hussain S; Mellor HR; Norris A; Park BK; Penrose A; Pritchard DM; Probert CS; Ramaiah S; Sadler C; Schmitt M; Shaw A; Sidaway JE; Vries RG; Wagoner M; Pirmohamed M
    Pharmacol Ther; 2017 Apr; 172():181-194. PubMed ID: 28132905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Introduction to nonclinical safety pharmacology and the safety pharmacology society.
    Bass AS; Vargas HM; Kinter LB
    J Pharmacol Toxicol Methods; 2004; 49(3):141-4. PubMed ID: 15172009
    [No Abstract]   [Full Text] [Related]  

  • 11. Is There a Space-Based Technology Solution to Problems with Preclinical Drug Toxicity Testing?
    Hammond T; Allen P; Birdsall H
    Pharm Res; 2016 Jul; 33(7):1545-51. PubMed ID: 27183841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in the development and use of human tissue-based techniques for drug toxicity testing.
    Clotworthy M; Archibald K
    Expert Opin Drug Metab Toxicol; 2013 Sep; 9(9):1155-69. PubMed ID: 23687950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of biopharmaceuticals in laboratory animals.
    Wierda D; Smith HW; Zwickl CM
    Toxicology; 2001 Feb; 158(1-2):71-4. PubMed ID: 11164995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The application of in vitro models of drug metabolism and toxicity in drug discovery and drug development.
    Ball SE; Scatina JA; Sisenwine SF; Fisher GL
    Drug Chem Toxicol; 1995 Feb; 18(1):1-28. PubMed ID: 7768197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zebrafish based assays for the assessment of cardiac, visual and gut function--potential safety screens for early drug discovery.
    Berghmans S; Butler P; Goldsmith P; Waldron G; Gardner I; Golder Z; Richards FM; Kimber G; Roach A; Alderton W; Fleming A
    J Pharmacol Toxicol Methods; 2008; 58(1):59-68. PubMed ID: 18585469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Troubleshooting computational methods in drug discovery.
    Kortagere S; Ekins S
    J Pharmacol Toxicol Methods; 2010; 61(2):67-75. PubMed ID: 20176118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is It Adverse, Nonadverse, Adaptive, or Artifact?
    Pandiri AR; Kerlin RL; Mann PC; Everds NE; Sharma AK; Myers LP; Steinbach TJ
    Toxicol Pathol; 2017 Jan; 45(1):238-247. PubMed ID: 27770107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-throughput assay development for combined in vitro toxicity screening of hit compounds and their metabolites in early drug-discovery stage.
    Siricilla S
    Bioanalysis; 2017 Jul; 9(13):959-961. PubMed ID: 28708435
    [No Abstract]   [Full Text] [Related]  

  • 19. Yeast as a humanized model organism for biotransformation-related toxicity.
    van Leeuwen JS; Vermeulen NP; Chris Vos J
    Curr Drug Metab; 2012 Dec; 13(10):1464-75. PubMed ID: 22935071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene Signatures Reduce the Stress of Preclinical Drug Hepatotoxicity Screening.
    Copple IM; Park BK; Goldring CE
    Hepatology; 2021 Jul; 74(1):513-515. PubMed ID: 33544908
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.